Ontvang nu dagelijks onze kooptips!

word abonnee
IEX 25 jaar
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   Accsys Technologies   /   Nieuwe overeenkomst met Solvay, cijfers 30 nov

Aandeel Accsys Technologies AEX:AXS.NL, GB00BQQFX454

Laatste koers (eur) Verschil Volume
0,555   +0,001   (+0,18%) Dagrange 0,545 - 0,566 254.060   Gem. (3M) 99,7K

Nieuwe overeenkomst met Solvay, cijfers 30 nov

Volgen
84 Posts
Pagina: «« 1 2 3 4 5 »» | Laatste | Omlaag ↓
  1. Pieter11 28 november 2015 23:24
    @ Jan Willem, Accsys gaat haar productie verdubbelen dus zal 40.000 m3/jaar erbij komen, deal met Solvay is een minimale afname van 76.000 m3 van 2016 tot 2020 dus over 5 jaar gemiddeld 76.000/5=15.200m3 en is dus een stuk minder dan de uitbreiding van de productie van Accsys. De productie uitbreiding zal dus niet volledig aan Solvay worden verkocht. Verder heb ik nergens vernomen dat er daadwerkelijk een proefinstallatie in gebruik is door Solvay. Als er al een proefinstallatie is, zal deze niet commercieel uit worden gebaat. Ik denk dan ook dat accoya tot nu toe altijd gewoon uit Arnhem vandaan is gekomen.
  3. Jan Willem 29 november 2015 12:09
    Bedankt voor je schrijven Pieter11, Ik waardeer je mening zéér en tenslotte zijn we gewoon een forum waarin wij allen een betrekking met de hout veredelaar Accsys hebben . Wel blijf ik erbij dat Solvay het zonder buffer niet gaat redden in 2019, en is het volgens mij ook niet zo dat een mogelijke nieuwe fabriek met diezelfde installaties als Accsys gaat werken, het kan ook zijn dat er al in de productie techniek een veel modernere versie is ontstaan waarmee er bijvoorbeeld nu ook met volledige stammen gewerkt kan worden . Knappe koppen hebben ze heus voldoende bij Solvay . mvg Jan Willem .
  4. Jan Willem 29 november 2015 12:47
    quote:

    Wouter139 schreef op 29 november 2015 11:52:

    Iemand er al eens aan gedacht dat Solvay uiteindelijk Accsys zou kunnen/willen overnemen? 1 grote fabriek in Arnhem is dan efficiënter dan 2 kleinere..
    Natuurlijk wel Wouter139 . Hier ging het wat vreemd op de vrijdag . Mocht er in de eerste weken een wat rustiger verloop optreden, is het zelfs mogelijk dat een grootaandeelhouder gestopt is met het dumpen van aandelen en verboden praktijken (schoonmaakploeg) Maar ik weet écht niet te vertellen om welke het gaat . mvg Jan Willem .
  9. Cementwagen 30 november 2015 08:46
    30 November 2015
    ACCSYS TECHNOLOGIES PLC (“Accsys” or “the Company”)
    INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2015
    Accsys, the chemical technology group, focused on the acetylation of wood, today announces interim results for the consolidated group for the six months ended 30 September 2015.
    AIM: AXS NYSE Euronext Amsterdam: AXS
    Unaudited six
    Unaudited six
    months ended months ended
    Total Group Revenue Gross Profit
    Underlying EBITDA* Underlying loss before tax* Loss before tax
    Period end cash balance
    30 Sept 2015
    €26.3m €9.4m €1.3m
    €(0.1m) €(0.1m) €7.5m
    30 Sept 2014
    €21.8m €5.0m €(1.9m) €(3.1m) €(6.2m) €13.5m
    Change
    +21%
    +88% Improved168% Improved97% Improved98%
    *Underlying EBITDA and loss before tax are stated before exceptional items of €nil (2014: €3.1m) recorded in respect of arbitration relating to the Diamond Wood licence agreement.
    Highlights
    ? Improved manufacturing margin together with an increase in revenue attributable to licensing and business development activities resulted in first positive EBITDA since restructuring in 2010;
    ? Continued trend of revenue growth in the period, with revenue increasing by 21% to €26.3m;
    ? Manufacturing segment profitability continues to improve, recording EBITDA of €5.0m (2014: €3.1m) as a result of higher prices and improved efficiency; gross manufacturing profit margin increased from 23% to 30%;
    ? Strong balance sheet maintained with cash balance of €7.5m at 30 September 2015;
    ? Cash in-flow from operating activities (before changes in working capital) of €1.8m (2014: out-flow of
    €0.7m excluding exceptional items) as a result of improvement in profitability;
    ? New agreement with Solvay signed since period end, for licencing, marketing and manufacturing of Accoya, including fees and funding to allow expansion of Accsys manufacturing capacity;
    ? Agreed minimum 76,000m3 off-take commitment from Solvay over next five years; and
    ? Proposed Tricoya consortium negotiations have progressed, with detailed engineering and site feasibility
    studies undertaken.
    Paul Clegg, Chief Executive commented: “Our latest set of results confirms that our manufacturing process generates increasing returns, giving us greater confidence to progress with our objective of ensuring we maintain a share in new manufacturing capacity. Not only have we seen a significant improvement in profitability in the period, but a number of important strategic steps have been taken in respect of the proposed formation of the new Tricoya consortium and the relationship with Solvay, enabling us to ensure that the ever-increasing demand for our products can be met in the future.”
  11. Cementwagen 30 november 2015 08:48
    Chairman’s statement
    Overview
    It is encouraging to be presenting the first set of results that are EBITDA positive since our restructuring in 2010. Accsys continues to make incremental improvements in manufacturing profitability which has been achieved through margin management. We are also seeing significant strategic developments as we exploit the opportunity that exists for our products and technologies.
    Revenue increased by 21% to €26.3m in the period reflecting increased prices and an increase in revenue attributable to our licencing and business development activities. Sales volumes were relatively flat as some distributors managed their inventories following price increases that we implemented to improve our profitability and to help manage our capacity utilisation. The increase in prices contributed to the significant improvement in profitability giving rise to a positive EBITDA of €1.3m (2014: €1.9m loss).
    Improved prices and an on-going focus on operating efficiencies resulted in an improvement in gross manufacturing profit margin which increased from 23% to 30% and with manufacturing segment EBITDA increasing by 62% to €5.0m. The manufacturing profitability continues to indicate the returns which we believe are achievable when producing greater volumes.
    Our balance sheet remains strong, with a cash balance of €7.5m as at 30 September 2015 (€10.8m as at 31 March 2015). Underlying cash flows from operating activities before changes in working capital improved from a €0.7m out-flow to a €1.8m in-flow with the decrease in cash in the period attributable to an increase in working capital of €3.1m. This included a notable build-up of inventories ahead of our scheduled annual maintenance stop in October such that we expect cash-flow to benefit from a reduction in working capital in the second half of the financial year.
    We recently announced a new agreement with Solvay Acetow Gmbh (“Solvay”), to refine the relationship between the two parties for the licensing, marketing and manufacturing of Accoya®. This new agreement provides the framework and funding for a significant increase in the manufacturing capacity at our plant in Arnhem.
    The enhanced relationship with Solvay will benefit both parties, with the increased manufacturing capacity and resulting sales expected to be achieved for Accoya in a faster timescale than would otherwise have been possible.
    A combination of loans and fees from Solvay, in addition to those due under a new offtake commitment, will fund the majority of the initial increase in manufacturing capacity at Arnhem, with the balance to be met by Accsys’ own resources, including the possible sale and leaseback of land at Arnhem.
    Following the acquisition of the remaining 50% in Tricoya Technologies Limited (‘TTL’) in March 2015, and the agreement of a Memorandum of Understanding with a large international chemical group (the ‘Chemical Group’) we have continued to progress towards the creation of a new consortium to fund, build and operate the world’s first Tricoya® acetylation plant. In addition to detailed negotiations with the proposed consortium partners, which also include Medite, we have completed the Front End Engineering and Design (‘FEED’) study necessary to progress to the construction stage. Detailed discussions continue between the parties with an intention of finalising the consortium ahead of the plant becoming operational by 2018 however further work is expected to be jointly funded before final consortium agreements are put in place.
    ?3
    Chairman’s statement Outlook
    The progress made with our key partners and the improvement in profitability represent significant developments for the Company as we continue towards our ambition of maximising the value associated with our technologies.
    In the immediate term we will continue to carefully manage the increasing demand for Accoya prior to additional capacity coming on stream in 2017, such that we expect revenue to continue to grow but at a smaller rate than that recorded in previous financial years.
    The new agreement with Solvay is particularly exciting and marks a significant step in the evolution of Accsys. It will enable us to significantly increase manufacturing capacity and to continue to develop markets on a global scale, whilst allowing us to take advantage of new opportunities and generate substantial group profits as production is ramped up.
    I am pleased with the progress being made in forming the proposed new Tricoya consortium and I am hopeful that the progress and efforts made by all of the proposed consortium partners will culminate in the new plant, further increasing manufacturing profits for the benefit of Accsys shareholders.
    Overall, I remain confident that we are in a strong position to continue our transition into a sustainable and profitable group focussed on commercialising our technologies through a balance of our own manufacturing capability and ongoing cooperation with strong industry partners.
    Patrick Shanley Chairman
    27 November 2015
  13. Cementwagen 30 november 2015 08:58
    Chief Executive’s statement
    Solvay and new manufacturing capacity in Arnhem
    We recently announced details of a new agreement with Solvay Acetow Gmbh (“Solvay”), to refine the relationship between the two parties for the licensing, marketing and manufacturing of Accoya®. This new agreement provides the framework and funding for a significant increase in the manufacturing capacity in Arnhem.
    Solvay will purchase a minimum 76,000m3 of Accoya from the Arnhem plant over the period from 2016 to 2020 (the “offtake commitment”) and as a result of the increased manufacturing capacity in Arnhem and consequent greater sales capacity, under the new agreement Solvay will review the optimal timing to construct its 63,000 m3 Accoya manufacturing plant.
    The enhanced relationship with Solvay will benefit both parties, with the increased manufacturing capacity and resulting sales expected to be achieved for Accoya in a faster timescale than would otherwise have been possible.
    Accsys will double the existing manufacturing capacity at its Arnhem site in stages, up to 80,000m3 per annum from 40,000m3. The initial incremental 20,000m3 capacity is expected to come on stream in mid-2017.
    The licence agreement covering Europe has been amended to provide increased royalties to Accsys and the return to Accsys of the selling rights for more than 20 European countries.
    Accsys will provide sales and marketing services to Solvay on agreed terms in respect of Solvay’s exclusive European territories.
    A combination of loans and fees from Solvay, in addition to those due under the offtake commitment, will fund the majority of the initial increase in manufacturing capacity at Arnhem, with the balance to be met by Accsys’ own resources, including the possible sale and leaseback of land at Arnhem.
    These agreements allow the market development of Accoya to continue and optimise the roll out of manufacturing capacity under its partnering program with Solvay, increasing the certainty of supply for Accoya customers and users. It also enables Accsys to continue to develop global markets effectively, building on the expertise that it has developed over the last few years.
    Tricoya® Technologies Limited (‘TTL’)
    In March 2015 we announced our intention to form a consortium to fund, construct and then operate the world’s first Tricoya® chip acetylation plant, following Accsys’s acquisition of the remaining 50% share in TTL from our former joint venture partner, Ineos.
    Since then, we have progressed detailed discussions with the proposed consortium partners, being the Chemical Group, with whom we signed a Memorandum of Understanding (MoU) in March 2015, and Medite, TTL’s joint development partner since 2009. A site feasibility study has been undertaken to determine that the proposed plant can be located on one of the Chemical Group’s existing production sites, which is expected to provide significant operational and construction benefits to the consortium.
    TTL engaged an engineering house to complete the Front End Engineering and Design study which will enable the next stage of detailed design and construction to commence, immediately after the consortium is formally put in place.
    During this period, Medite Tricoya® has continued to be manufactured using Accoya sold by Accsys to Medite using a temporary process, pending construction of the dedicated Tricoya plant. However this has enabled sales of Medite Tricoya to grow, with sales volumes of Medite Tricoya panels increasing by 14% in the calendar year to October .
    Masisa, TTL’s licence option holder in Latin America, has also continued to progress its market development activities, with Masisa Tricoya XB being specified in an increasing number of projects.
    ?6
    Accsys Technologies PLC Chief Executive’s statement Intellectual property
    Accsys has considerably increased its number of patent applications in the recent period by expanding its patent families to 22, including those relating to Tricoya®. Applications filed now number 191, filed in 43 countries. To date 42 patents have been granted in various countries throughout the world.
    Our principal trademark portfolio remains unchanged with our brands Accoya®, Tricoya®, the Trimarque device and Accsys®, including transliterations in Arabic, Chinese and Japanese, protected by registration in 56 countries. The Company’s patents and trademarks cover the products we and our distributors and licensees sell, and the processes by which these products are made, throughout the world.
    In addition to Accsys’s extensive patent and trade-mark portfolio, the Company continues to invest in the generation and protection of valuable know-how and confidential information relating to its products and processes, protected by way of confidentiality protocols and contractual agreements.
    Outlook
    We are pleased to be able to cement our relationship with Solvay to expand our Accoya manufacturing capacity and Solvay’s commitment to purchase significant volumes from Accsys over the coming years. This is an exciting step in the development of our business and is further evidence of the execution of our strategy to maximise returns from our technology platform and our innovative products.
    The proposed consortium with the Chemical Group and Medite, for the funding, construction and operation of the first Tricoya® chip acetylation plant is progressing well and I remain confident that Tricoya® remains a substantial and exciting opportunity for us.
    Both developments represent a way for Accsys to participate directly in the manufacture of higher volumes of our products than we have previously envisaged. I believe this model, where we seek to obtain a greater share of manufacturing margins while continuing to work with strong industry partners through licensing and joint venture activities puts us in a strong position to be able to grow shareholder value.
    In the immediate future, we will continue to carefully manage operations to ensure optimal management of our existing manufacturing capacity, working capital and costs such that we maintain sufficient resources to meet the demands of the next exciting period of our development.
    Paul Clegg
    Chief Executive
    27 November 2015
  16. pardon 30 november 2015 09:18
    Een vijfde meer omzet voor Accsys
    Gepubliceerd op 30 nov 2015 om 08:39 |
    Accsys 27 nov
    0,99 0,00 (0,00%)

    AMSTERDAM (AFN) - Houtveredelaar Accsys heeft in de zes maanden tot en met eind september een omzet behaald van 26,3 miljoen euro. Dat is ruim een vijfde meer dan in dezelfde periode vorig jaar. De brutowinst verdubbelde bijna tot 9,4 miljoen euro, meldde de onderneming maandag.

    Het onderliggend bedrijfsresultaat (ebitda) kwam uit op 1,3 miljoen euro, tegen 1,9 miljoen euro negatief een jaar eerder. Accsys boekte nog wel een klein verlies voor belastingen, van 0,1 miljoen euro. Een jaar eerder kwam het tekort nog uit op 6,2 miljoen euro.

    - See more at: www.debeurs.nl/Beursnieuws/ANP-301115...
  17. Cementwagen 30 november 2015 09:19
    Accsys behaalt hogere omzet

    AMSTERDAM (Dow Jones)--Accsys Technologies plc (AXS.LN) heeft de afgelopen zes maanden de omzet zien stijgen en wist het resultaat te verbeteren, onder meer dankzij hogere licentie-inkomsten.

    De omzet over het eerste halfjaar van het gebroken boekjaar nam toe tot EUR26,3 miljoen van EUR21,8 miljoen een jaar terug. De onderliggende winst voor rente, belasting, afschrijving en amortisatie (EBITDA) verbeterde tot EUR1,3 miljoen positief van EUR1,9 miljoen negatief een jaar terug.

    Een verbetering van de marge en een toename van de inkomsten uit licenties resulteerden in de eerste positieve EBITDA sinds 2010, aldus Accsys.


    Dow Jones Nieuwsdienst; +31-20-5715200; amsterdam@dowjones.com


    (END) Dow Jones Newswires

    November 30, 2015 03:08 ET (08:08 GMT)

    *Binck is niet aansprakelijk voor informatie verschaft door derden
  19. [verwijderd] 30 november 2015 09:30
    quote:

    Cementwagen schreef op 30 november 2015 09:21:

    Heb nog niets gevonden over Diamond Wood, wellicht bij de conference call.

    De cijfers en toelichting zien er bemoedigend uit.
    alleen dat ze daar nog niet veel afzet hebben,lees orders, van DW,maar overall zeer mooi,going up to the next level...
84 Posts
Pagina: «« 1 2 3 4 5 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium

Accsys slikt bittere pil en sloopt fabriek Hull

Het laatste advies leest u als abonnee van IEX Premium

Inloggen Word Abonnee

Accsys Nieuws

  1. Slotcall: Arcelor, Aperam en Prosus hoger gezet na opluchting over China
  2. Nieuwe CFO voor Accsys
  3. Accsys zet punt achter fabriek in het Britse Hull
  4. Beursblik: goede jaarstart voor Accsys
  5. Beursblik: aandeel Accsys presteert goed
  6. Bescheiden omzetgroei Accsys
  7. Slotcall: sentiment draait, koers Alfen doormidden en forse dreun Accsys en Ebusco
  8. Omzet Accsys onder druk
  9. CFO Accsys vertrekt alweer
  10. Deutsche Bank start volgen Accsys met koopadvies